



# Small bowel tumours



- ▶ Only 1 to 2 per cent of malignant alimentary **tumours**.
- ▶ Equal between man and women
- ▶ 100 times less frequent than in the stomach, oesophagus, or colorectum
- ▶ Benign lesions are more common distal, while Adenocarcinoma is more common proximal.



- ▶ Small intestinal tumors may originate in cells of the:
  - ▶ epithelium
    - ▶ adenomas,
    - ▶ adenocarcinomas or
    - ▶ carcinoids
  - ▶ lymphatic tissues
    - ▶ lymphomas
  - ▶ mesenchymal or neural elements
    - ▶ gastrointestinal stromal tumors
    - ▶ leiomyomas
    - ▶ lipomas
    - ▶ hemangiomas
    - ▶ neuromas
    - ▶ sarcomas

# Risk factors



- ▶ Familial adenomatous polyposis,
- ▶ Hereditary nonpolyposis colorectal cancer (HNPCC),
- ▶ Peutz-Jeghers syndrome,
- ▶ Crohn's disease,
- ▶ Gluten-sensitive enteropathy (celiac sprue),
- ▶ Biliary diversion (e.g., previous cholecystectomy).

# Presentation



- ▶ Sixth and seventh decades of life
- ▶ Benign **tumours** are found incidentally at laparotomy or autopsy
  - ▶ vague symptoms, absence of clinical signs, the difficulty in investigating much of the **small bowel**
  - ▶ nausea, dyspepsia, epigastric discomfort, fatigue, bloating and weight loss, to haemorrhage or obstruction
  - ▶ Haemorrhage: occult or major bleeding ..
  - ▶ palpable abdominal mass, perforation, fistula formation, intussusception or intraperitoneal haemorrhage



# CLINICAL PRESENTATION OF PRIMARY SMALL BOWEL TUMORS



Signs and symptoms	Frequency (%)
<b>BENIGN NEOPLASMS</b>	
Asymptomatic	47–60
Abdominal pain	24–50
Acute gastrointestinal hemorrhage	29–44
Anemia	28–58
Intermittent obstruction	12–28
<b>MALIGNANT NEOPLASMS</b>	
Asymptomatic	6–12
Abdominal pain	62–83
Weight loss	38–55
Nausea/vomiting	23–64
Acute gastrointestinal hemorrhage	6–31
Anemia	12–38
Abdominal mass	5–32


# Investigation



- ▶ Contrast Studies : small bowel follow through
- ▶ Endoscopy
- ▶ CT / MRI
- ▶ Angiography
- ▶ Capsule endoscopy




# small bowel follow through





# CT entorography







Activate  
Go to Sett

# Pathological classification



- ▶ Not straightforward
  - ▶ *Benign neoplasms*
  - ▶ *Malignant Tumours*





# Adenoma

- ▶ True adenoma, Villous adenoma and Brunner gland adenoma.
- ▶ 20% in duodenum, 30 % in jejunum and 50% in ileum.
- ▶ Villous adenomas more common in Duodenum and less common in distal small bowel.
- ▶ Most common presentation is asymptomatic, Abdominal pain, obstruction, and occult (or overt) haemorrhage Obstructive jaundice.
- ▶ Malignant change increases with the **size, site**, and **number** of lesions as well as with the histological type ( **tumours** situated in the periampullary region are more prone to malignancy)





# Familial Polyposis syndromes



- ▶ Familial polyposis coli
- ▶ Autosomal-dominant inheritance of the mutated *APC* gene
- ▶ Thousands of adenomas in the colorectum
- ▶ polyps occur within the **small** intestine in 24 to 93 per cent
- ▶ only **2 to 12 per cent** develop duodenal cancer
- ▶ Treatment : excise polyps / biopsy / follow up

# Other Benign neoplasms



- ▶ **Brunner's gland adenoma ( duodenum)**
- ▶ **Lipoma**
- ▶ Neurofibromas
- ▶ **Fibroma**
- ▶ **Vascular tumours**
- ▶ **Leiomyoma**



# Malignant Tumours of Small Intestine

- ▶ Malignant neoplasms almost always produce symptoms
- ▶ The most common :pain and weight loss
  - ▶ Obstruction in 15- 35% of patients ( adhesions and infiltration)
  - ▶ Diarrhoea and excess mucus
  - ▶ GI bleeding , anaemia



# Carcinoid tumours

- ▶ Originate in enterochromaffin cells (*argentaffin cells*)
- ▶ 0.7 per 100 000
- ▶ These **tumours** may occur in the
  - ▶ foregut (including the duodenum),
  - ▶ midgut (including the jejunoileum),
  - ▶ the hind gut.
- ▶ Midgut carcinoids characteristically secrete large amounts of 5-hydroxytryptamine (**5-HT**; serotonin), whereas foregut carcinoids secrete **small** amounts of this peptide





# Carcinoid tumours cont.

- ▶ Most common in ileum ( last two feet)
- ▶ Multi-centric in 30 – 40 % of cases
- ▶ yellow in colour and appear in a submucosal or serosal position
- ▶ slow-growing **tumours**
- ▶ fifth decade, and both sexes are affected equally.
- ▶ Most common presentation is **pain**.
- ▶ Most patients will have metastasized to LN / Liver
- ▶ Doudenal carcinoid can cause ulceration, obstruction, and jaundice



# Carcinoid **tumours** malignant potential

- ▶ Metastasis is related to size of tumor,
  - ▶ Less than 1cm tumor : 20 – 30 % risk of mets to LN and liver
  - ▶ 1–2 cm tumor: 60-80% LN and 20% Liver
  - ▶ More than 2cm : 80% LN and 40-50% liver
- ▶ Lesion less than 1cm can be adequately treated with local excision.
- ▶ **Small bowel obstruction, mesenteric fibrosis and ischaemia.**



# Carcinoid syndrome.



- ▶ Carcinoid syndrome refers to **vasomotor**, **gastrointestinal**, and **cardiac** manifestations induced by systemic circulation of a variety of peptides elaborated by carcinoid tumor
  - ▶ *Diarrhoea, flushing, wheezes, abdominal cramps, cardiac (Rt heart failure)*
  - ▶ *Most likely liver metastases or large tumor bypass the liver*
- ▶ Elevated urinary levels of 5-HIAA measured over 24 hours with high-performance liquid chromatography are highly specific but not sensitive

# Carcinoid Tumours Cont.



- ▶ Treatment
- ▶ Local disease : resection including draining Lymph nodes
- ▶ Metastatic disease:
  - ▶ Tumour debulking, resection, cryotherapy, radiofrequency ablation, hepatic artery embolization, or chemoembolization.
- ▶ Systemic therapy
  - ▶ Somatostatin analogs. Octeriotide, Long-acting octreotide, lanreotide.
- ▶ Cytotoxic chemotherapy: ineffective.

# Adenocarcinoma



- ▶ Adenocarcinoma accounts for about 35% of **small bowel tumors**
- ▶ More common in proximal small bowel than distal.
- ▶ median age at presentation of 60 years
- ▶ Presentation according to site:
  - ▶ Non-specific, vomiting, pain , jaundice, obstruction, perforation.
- ▶ Jejunal and ileal **tumours** are best treated by segmental resection including the regional lymph nodes
- ▶ The overall 5-year survival rate for jejunoileal carcinomas is **20 to 30** per cent. If there is no nodal involvement at operation, survival is increased to **50 to 70** per cent
- ▶ Chemotherapy is of little help.

# Adenocarcinoma cont.



- ▶ Adenocarcinoma developing with **crohn's disease** is more common in ileum
- ▶ 20 years younger
- ▶ male preponderance of about 70 per cent
- ▶ prognosis is very poor





# Gastrointestinal lymphoma

- ▶ 1 to 4 per cent of all primary gastrointestinal cancers
- ▶ 50 to 55 per cent of **tumours** occur in the stomach, 30 to 32 per cent in the **small bowel**
- ▶ Present with; obstruction, bleeding , anorexia and weight loss .
- ▶ 5<sup>th</sup> and 6<sup>th</sup> decade
- ▶ Most common in ileum
- ▶ Increase incidence in patients with **Coeliac disease / immunodeficiency states** (e.g., AIDS).
  - ▶ Worsening diarrhea, pyrexia, and local obstructive symptoms.
- ▶ Treatment is usually medical unless surgical complication.



# Gastrointestinal Stromal Tumours (GIST)

- ▶ Arise from Connective tissue cells
- ▶ Most common mesenchymal tumour of the GI Tract.
- ▶ Benign or malignant. Size increase risk of malignant potential.
- ▶ Usually stomach followed by small bowel ( jejunum > ileum)
- ▶ 50-70 years of age.





# GIST *cont.*

- ▶ Lymphatic spread is not common
- ▶ Metastasis to liver or peritoneum
  
- ▶ Prognosis
  - ▶ Worse than in stomach and oesophagus
  - ▶ Tumour size : less than 2 cm diameter → low risk
  - ▶ Mitotic rate: less than 5 HPF → low risk



## ▶ Treatment

- ▶ Surgery . Excision with negative margin
- ▶ Tyronise kinase inhibitor ( imatinib) in **advanced cases** 50% tumours shrinkage.
- ▶ Radio-resistant



# End of notes